### Japan

**Population 2018**: 127 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>18 (15–21)</td>
<td>14 (12–16)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.1 (0.031–0.21)</td>
<td>0.06 (0.02–0.17)</td>
</tr>
<tr>
<td>MDR-RR-TB incidence**</td>
<td>0.51 (0.22–0.93)</td>
<td>0.4 (0.17–0.73)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>2.8 (2.6–2.9)</td>
<td>2.2 (2.1–2.3)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.016 (&lt;0.01–0.034)</td>
<td>0.01 (0–0.03)</td>
</tr>
</tbody>
</table>

- **Estimated proportion of TB cases with MDR/RR-TB, 2018**
  - New cases: 2.3%
  - Previously treated cases: 11% (6.1–17%)

- **TB case notifications, 2018**
  - Total new and relapse: 15,590
    - % tested with rapid diagnostics at time of diagnosis:
      - % with known HIV status: 8%
      - % pulmonary: 77%
      - % bacteriologically confirmed**: 86%
      - % children aged 0–14 years: 1%
      - % women: 40%
      - % men: 59%
  - Total cases notified: 15,590

- **Universal health coverage and social protection**
  - TB treatment coverage (notified/estimated incidence), 2018: 87% (75–100)
  - TB patients facing catastrophic total costs: 16% (13–18)

- **TB/HIV care in new and relapse TB patients, 2018**
  - Patients with known HIV status who are HIV-positive: 44% 3%
    - on antiretroviral therapy

- **Drug-resistant TB care, 2018**
  - % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 74%
    - New cases: 74%
    - Previously treated cases: 67%

- **MDR/RR-TB cases tested for resistance to second-line drugs**

- **Treatment success rate and cohort size**
  - New and relapse cases registered in 2017: 68% 16,702
  - Previously treated cases, excluding relapse, registered in 2017: 65% 31
  - MDR-RR-TB cases started on second-line treatment in 2016: 52% 56
  - XDR-TB cases started on second-line treatment in 2016: 52% 56

- **TB preventive treatment, 2018**
  - % of HIV-positive people (newly enrolled in care) on preventive treatment: 62% (46–96)
  - % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 62% (46–96)

- **TB financing, 2019**
  - National TB budget (US$ millions)

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
**: Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2019-10-18